|
http://www.clinicaltrials.gov/ct/show/NCT00061477?amp;order=10
Trial Information
The purposes of this study are to determine -
- The safety of ALIMTA plus Gemcitabine (Gemzar) and any side
effects that might be associated with the combination of these two
drugs.
- Whether ALIMTA plus Gemcitabine (Gemzar) can help patients with
mesothelioma live longer.
- Whether ALIMTA plus Gemcitabine (Gemzar) can make the tumor
smaller or disappear, and for how long.
- To see if patients feel better while taking ALIMTA plus
Gemcitabine (Gemzar).
Inclusion Criteria:
- Diagnosis of mesothelioma that can be treated with chemotherapy
- Have received no prior chemotherapy for mesothelioma
- Have at least one measurable lesion
- Have an adequate performance status
- Have signed an informed consent
Exclusion Criteria:
- Previous treatment with chemotherapy for mesothelioma
- Treatment with an investigational drug within the last 30 days,
previously completed or withdrawn from this study or any other
study investigating ALIMTA
- Treatment with radiation therapy within the last 4 weeks
- Brain metastasis that is uncontrolled
- Active infection or other serious condition
Please note that more specific inclusion/exclusion criteria must be
met prior to entering the trial.
For additional information regarding this trial contact the
Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or
speak with your personal physician.
ALIMTA Plus Gemcitabine (Gemzar) for Patients with Malignant
Pleural or Peritoneal Mesothelioma who have not had previous
chemotherapy
Locations:
- Research Center Located in: Aurora, CO
- Research Center Located in: Tampa, FL
- Research Center Located in: Chicago, IL
- Research Center Located in: Baltimore, MD
- Research Center Located in: Boston, MA
- Research Center Located in: Albuquerque, NM
- Research Center Located in: New York, NY
- Research Center Located in: Madison, WI
Telephone: 877-CTLILLY (1-877-285-4559)
Trial listings updated: September 11, 2003 at 10:50:19 AM
*** POSTED SEPTEMBER 19, 2003 ***
|